FBC Cavuto Coast To Coast July 11, 2024
Reporter neil, good afternoon to you. Start with astrazeneca. That is the top headline. It is covid19 vaccine as you mentioned having a good immune response in older results this is a phase two trial. Heefficacy will not be done untl they resume phase three trials you mentioned pfizer around biontech, they will file for their emergency approval with the fda form for the covid19 that tells us they are on track for the timeline they promised. Johnson johnson ready to have its vaccine ready for approval by february of 2021. Like i said, a bunch of different choices here. New york city in a little...